EMa Grants Lisata Therapeutics Paediatric Investigation Plan Waiver For Certepetide In Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has granted Lisata Therapeutics a waiver for paediatric investigation plans for their drug, certepetide, in pancreatic cancer. This waiver means that paediatric studies are not required, thereby avoiding significant clinical trial burdens and costs.
May 20, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lisata Therapeutics received a waiver from the EMA for paediatric studies of certepetide in pancreatic cancer, reducing clinical trial burdens and costs.
The waiver from the EMA eliminates the need for paediatric studies, which reduces the clinical trial burden and associated costs for Lisata Therapeutics. This is likely to have a positive short-term impact on the stock price as it improves the company's financial outlook and accelerates the drug's development timeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100